SUPPORT FOR NATIONAL PRIMATE RESEARCH CENTER Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing NCI-designated Comprehensive Cancer Research Center dedicated to research and training, with the mission of changing and setting the standards of treatment, prevention and control of cancer through inpatient and outpatient care. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Molecular Structure); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Survivorship, Outcomes and Risk). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based Investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the 10 research programs depends on services provided by 34 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 21 of these core facilities. During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs in key research areas. Support is requested to provide developmental funding for the laboratories of new Investigators recruited in research areas aligned with the Center's strategic vision, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Public Health Relevance

Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-52S1
Application #
9624052
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2018-12-31
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
52
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Thom, Bridgette; Benedict, Catherine; Friedman, Danielle N et al. (2018) The intersection of financial toxicity and family building in young adult cancer survivors. Cancer 124:3284-3289
Busque, Lambert; Buscarlet, Manuel; Mollica, Luigina et al. (2018) Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil. Stem Cells 36:1287-1294
Elterman, Dean S; Chughtai, Bilal; Vertosick, Emily et al. (2018) Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder. Female Pelvic Med Reconstr Surg 24:264-266
Beckham, Thomas H; Romesser, Paul B; Groen, Andries H et al. (2018) Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. Thyroid 28:1180-1189
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Meyer, Jan-Philip; Tully, Kathryn M; Jackson, James et al. (2018) Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. Bioconjug Chem 29:538-545
McFarland, Daniel C; Shaffer, Kelly; Breitbart, William et al. (2018) C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer. Cancer :
Lacouture, Mario E; Anadkat, Milan; Jatoi, Aminah et al. (2018) Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 17:85-96
Blumenthal, Gideon M; Bunn Jr, Paul A; Chaft, Jamie E et al. (2018) Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 13:1818-1831

Showing the most recent 10 out of 8799 publications